NEUROCRINE BIOSCIENCES INC

Insider buys at Neurocrine reveal confidence in its neuro‑psychiatric pipeline and upside potential—see how the CEO’s 10b5‑1 trades signal long‑term optimism.

Neurocrine insider trading: Lippoldt Darin’s 10(b)(5) buys and sells reveal disciplined portfolio management, reinforcing investor confidence in the company’s neuro‑psychiatric pipeline.

Neurocrine insider trading: Mr. Stephan’s disciplined 10b‑5‑1 buy‑sell cycle shows confidence in INGREZZA and a cautious, rule‑based accumulation strategy for long‑term investors.

Neurocrine insider activity shows balanced buying and selling, with HR chief Julie Cooke buying at $81.49 while selling at $155‑$158, hinting at long‑term confidence yet risk‑aware moves.

Neurocrine insider trading: a director’s buy at $47.89 and sell at $157.65 shows long‑term confidence and market stability—why investors should watch upcoming trials.

Neurocrine insider sells 3,810 shares via 10b5‑1 plan, signaling strategic divestment while market remains bullish and investor confidence stays high.

Insider trading at Neurocrine Biosciences shows steady confidence: executives buy/sell for liquidity but maintain long‑term stakes, keeping volatility low and focusing on future neuro‑psychiatric breakthroughs.

Insider buying surge at Neurocrine shows executive confidence ahead of Phase 2 data; could lift the stock toward its recent high.

Neurocrine CFO’s fresh buy signals insider confidence amid rising stock, highlighting upcoming Phase‑2 data that could boost a biotech rally.

Neurocrine insider Bénévich’s 12,830‑share option exercise signals strong confidence in its pipeline and may boost investor sentiment ahead of earnings.